CIP2A and breast carcinoma: MiPEP133 binds HSPA9 in mitochondria, prevents HSPA9 from interacting with HSP60, TIM44, and VDAC1, and inhibits the normal function of HSPA9 as a mitochondrial companion, eventually leading to mitochondrial mass loss, reduced mitochondrial membrane potential and ATP production [169].In the ncRNA study for breast cancer, LINC00665 has four sORFs, in which ORF1 encodes the CIP2A binding peptide CIP2A-BP.